Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Phase 2

Terminated

Conditions: Recurrent Uterine Sarcoma
Uterine Carcinosarcoma

Interventions: Drug: temsirolimus

First Posted Date: 2010-02-03

Last Posted Date: 2016-11-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT01061606

Locations: 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
City of Hope Medical Group Inc, Pasadena, California, United States
🇺🇸
Women's Cancer Care Associates LLC, Albany, New York, United States

and more 17 locations

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Anaplastic Astrocytoma
Adult Diffuse Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Glioblastoma
Adult Mixed Glioma
Adult Oligodendroglioma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Perifosine
Drug: Temsirolimus
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2010-01-18

Last Posted Date: 2021-07-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT01051557

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Stage IV Prostate Cancer
Hormone-Resistant Prostate Cancer
Recurrent Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Biological: Cixutumumab
Other: Diagnostic Laboratory Biomarker Analysis
Drug: Temsirolimus

First Posted Date: 2009-12-04

Last Posted Date: 2019-06-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT01026623

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

and more 1 locations

Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Recurrent Cervical Carcinoma
Cervical Adenosquamous Carcinoma
Stage IVA Cervical Cancer
Cervical Squamous Cell Carcinoma
Stage IIIA Cervical Cancer
Cervical Adenocarcinoma
Stage IIIB Cervical Cancer
Stage IVB Cervical Cancer

Interventions: Drug: Temsirolimus
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-12-04

Last Posted Date: 2015-09-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT01026792

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer
Metastatic Disease
Prostatic Neoplasms
Castrate-resistant Prostate Cancer (CRPC)
Androgen-insensitive Prostate Cancer
Hormone-refractory Prostate Cancer

Interventions: Drug: Temsirolimus
Drug: Casodex (bicalutamide)

First Posted Date: 2009-11-25

Last Posted Date: 2014-10-13

Lead Sponsor: Sandy Srinivas

Target Recruit Count: 5

Registration Number: NCT01020305

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: temsirolimus
Drug: temozolomide

First Posted Date: 2009-11-25

Last Posted Date: 2018-07-09

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 111

Registration Number: NCT01019434

Locations: 🇮🇹
Ospedale Bellaria, Bologna, Italy
🇧🇪
UZ Leuven, Leuven, Belgium
🇳🇱
Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands

and more 10 locations

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck

First Posted Date: 2009-11-18

Last Posted Date: 2012-12-17

Lead Sponsor: University of Tennessee Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01015664

Locations: 🇺🇸
Boston Baskin Caner Foundation, Memphis, Tennessee, United States

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Phase 2

Completed

Conditions: Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Metastatic Osteosarcoma
Recurrent Osteosarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Biological: Cixutumumab
Other: Laboratory Biomarker Analysis
Drug: Temsirolimus

First Posted Date: 2009-11-18

Last Posted Date: 2015-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 178

Registration Number: NCT01016015

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 21 locations

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Phase 2

Completed

Conditions: Adult Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Endometrial Serous Adenocarcinoma
Localized Non-Resectable Adult Liver Carcinoma
Lung Carcinoid Tumor
Malignant Pancreatic Gastrinoma
Malignant Pancreatic Glucagonoma
Malignant Pancreatic Insulinoma
Malignant Pancreatic Somatostatinoma
Metastatic Digestive System Neuroendocrine Tumor G1

Interventions: Biological: Bevacizumab
Drug: Temsirolimus

First Posted Date: 2009-11-09

Last Posted Date: 2019-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 252

Registration Number: NCT01010126

Locations: 🇺🇸
University of Connecticut, Farmington, Connecticut, United States
🇺🇸
Cancer Care Center of Decatur, Decatur, Illinois, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 58 locations

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma

Interventions: Drug: Erlotinib
Drug: Temsirolimus

First Posted Date: 2009-11-06

Last Posted Date: 2015-08-10

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 13

Registration Number: NCT01009203

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy